Gavin Screaton

Title: Gavin Screaton: Innovator in Dengue and Flavivirus Research

Introduction

Gavin Screaton is a prominent inventor based in London, GB. He has made significant contributions to the field of virology, particularly in the development of vaccines and antibodies against dengue and other flaviviruses. With a total of 3 patents, his work is crucial in advancing medical science and public health.

Latest Patents

Screaton's latest patents focus on anti-dengue vaccines and antibodies. One of his notable inventions is a Dengue virus Envelope Dimer Epitope (EDE). This EDE spans the polypeptides of a Dengue virus Envelope polypeptide dimer and is presented on a dimer of Envelope proteins. The EDE is formed from consecutive or nonconsecutive residues of the envelope polypeptide dimer, which can be a homodimer or heterodimer of native and/or mutant envelope polypeptides from DENV-1, DENV-2, DENV-3, and DENV-4. Additionally, he has developed a neutralizing antibody against dengue for use in preventing and treating Zika infection. This involves a flavivirus Envelope Dimer Epitope and isolated neutralizing antibodies directed against the EDE.

Career Highlights

Gavin Screaton has worked with prestigious institutions such as Institut Pasteur and Imperial College Innovations Limited. His research has been pivotal in understanding and combating flavivirus infections, contributing to the development of effective vaccines.

Collaborations

Screaton has collaborated with notable scientists, including Marie-Christine Vaney and Juthathip Mongkolsapaya. These partnerships have enhanced the depth and impact of his research in the field of virology.

Conclusion

Gavin Screaton's innovative work in the development of vaccines and antibodies against dengue and other flaviviruses showcases his dedication to improving global health. His contributions are vital in the ongoing fight against viral infections.